A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer following First Line Platinum Based Chemotherapy
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Olaparib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Acronyms OSTRIA1; SOLO1
- Sponsors AstraZeneca
- 29 Nov 2017 Planned primary completion date changed from 13 Sep 2017 to 15 May 2018.
- 10 Jun 2017 Biomarkers information updated
- 24 Nov 2016 Planned End Date changed from 1 Jan 2023 to 1 Mar 2023.